Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR somatic variants status confers therapeutic sensitivity to Afatinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).